Category: Administering Enema

Administering Enema – Administering.net

FDA Drug Safety Communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation

View and print full Drug Safety Communication (PDF – 218KB)[1] Safety Announcement [1-8-2014] The U.S. Food and Drug Administration (FDA) is warning that using more than one dose in 24 hours of over-the-counter (OTC) sodium phosphate drugs to treat constipation can cause rare but serious harm to the kidneys and heart, and even death. OTC sodium phosphate drug products include...

READ MORE FDA Drug Safety Communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation

Perforation and mortality after cleansing enema for acute constipation are not rare but are preventable

Int J Gen Med. 2013; 6: 323–328. This article has been cited by[1] other articles in PMC. Abstract Objectives Constipation is a common complaint, frequently treated with cleansing enema. Enemas can be very effective but may cause serious adverse events, such as perforation or metabolic derangement. Our aim was to evaluate the outcome of the use of cleansing enema for...

READ MORE Perforation and mortality after cleansing enema for acute constipation are not rare but are preventable

Why Does This Patient Have Acute Severe Abdominal Pain Following Barium Enema

One day following sigmoidoscopy for an anal stricture, this 61-year-old obese woman was admitted to the emergency department in shock. Earlier that morning, she had a barium enema without evidence of free air inferior to the diaphragm. Acute abdominal pain developed several hours later. Radiographs on admission revealed extravasation of barium into the peritoneal cavity. On the second hospital day,...

READ MORE Why Does This Patient Have Acute Severe Abdominal Pain Following Barium Enema

Cosmo announces European approval of Qolotag® for sigmoidoscopies in IBD patients

Dublin – July 26, 2017 – Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that its medical device Qolotag® has been granted the CE mark and the approval for marketing in the EU. Qolotag® is a liquid, blue coloured emulsion developed by Cosmo as an enema formulation to be used for the mechanical cleansing, and simultaneous staining, of the sigmoid colon...

READ MORE Cosmo announces European approval of Qolotag® for sigmoidoscopies in IBD patients